Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third View: Perusing the data from the CARTITUDE-4 clinical trial of Carvykti for multiple myeloma which was presented at the 2024 International Myeloma Society Annual Meeting.

Ticker(s): LEGN, JNJ

Who's the expert?

Institution: Rutgers University

Assistant professor at Rutgers University and medical hematologist oncologist.
Currently manages 35 patients for Sickle cell disease

Interview Goal

To discuss the current treatment landscape and the potential of Carvykti (ciltacabtagene autoleucel; cilta-cel), a CAR-T therapy developed by Johnson & Johnson and Legend Biotech for the treatment of multiple myeloma.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.